Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01288261 · ClinicalTrials.gov registry record · Phase 1
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
A Phase 1 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01288261 is a Phase 1 study that has completed, run by University of Arizona. The registered enrollment target is 14 participants.
The verdict
NCT01288261, a Phase 1 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bavituximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving paclitaxel together with bavituximab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving paclitaxel and bavituximab together in treating patients with Human Epidermal growth factor Receptor 2 (HER2 )-negative metastatic breast cancer
Interventions
- OTHER laboratory biomarker analysis
- DRUG paclitaxel
- OTHER pharmacological study
- BIOLOGICAL bavituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01288261
The ClinicalTrials.gov registry entry for NCT01288261 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01288261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01288261 about?
NCT01288261 is a clinical study titled "Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bavituximab, can block tumor growth in different ways. Some block the ability of tumor ce...
What is the current status of trial NCT01288261?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-01. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01288261?
The interventions under investigation include: laboratory biomarker analysis (OTHER), paclitaxel (DRUG), pharmacological study (OTHER), bavituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01288261?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.